triheptanoin


( Last Updated : April 28, 2021)
Generic Name:
triheptanoin
Project Status:
Active
Therapeutic Area:
Long-chain fatty acid oxidation disorders
Manufacturer:
Ultragenyx Canada Inc
Call for patient/clinician input open:
Brand Name:
Dojolvi
Project Line:
Reimbursement Review
Project Number:
SR0684-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
Ultragenyx is requesting triheptanoin be reimbursed for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD)
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Dojolvi (triheptanoin) is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD). ​
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openFebruary 26, 2021
Call for patient/clinician input closedApril 23, 2021
Clarification:

- Patient input submission received from MitoAction

Submission receivedMarch 31, 2021
Submission acceptedApril 15, 2021
Review initiatedApril 16, 2021
Draft CADTH review report(s) provided to sponsor for commentJune 30, 2021
Deadline for sponsors commentsJuly 12, 2021
CADTH responses on draft review report(s) provided to sponsorAugust 06, 2021
Expert committee meeting (initial)August 18, 2021
Draft recommendation issued to sponsorAugust 30, 2021
To
September 01, 2021
Draft recommendation posted for stakeholder feedback-